C. Richard (Rick) Boland MD is Chief of Gastroenterology at Baylor University Medical Center (BUMC) in Dallas, Texas. He was born and raised in upstate New York, received a B.A. from The University of Notre Dame in 1969 and an M.D. from Yale Medical School in 1973. He has a career-long research interest in colon cancer, specifically focusing on the genetic causes of colon cancer and familial cancer syndromes. His academic career included appointments at UCSF (1978-84), the University of Michigan (1984-95), and UCSD, where he was Professor of Medicine and Chief of the GI Division from 1995-2003. He moved to BUMC in 2003 for an endowed chair, where he has focused entirely on colon cancer research with both laboratory-based and clinical programs designed to accelerate the translation of basic concepts into diagnostic, preventive, and therapeutic approaches for clinical medicine.
Rick started studying familial colorectal cancer as a medical student, and wrote an MD thesis proposing a novel familial aspect of the disease. After clinical training (and a stint as a general medical officer in the Indian Health Service), he resumed research with Young S. Kim, M.D. at UCSF, studying glycoprotein biochemistry in colorectal cancer. At the University of Michigan, he continued work on cancer-associated glycoprotein alterations, but in 1990, he redirected his focus to the molecular genetics of colorectal cancer following a sabbatical in the Howard Hughes Medical Institute, at which time he resumed work on the hereditary colorectal cancer disease, which he named “Lynch Syndrome”. He was among the first gastroenterologists to explore “microsatellite instability” in cancer, and his laboratory developed the first in vitro models to study the basic biology of Lynch Syndrome, using stable chromosome transfer to correct DNA mismatch repair (MMR) deficiencies in cultured cells. These models demonstrated the role of the DNA MMR system in the regulation of the cell cycle, and demonstrated that this system was involved in tumor cell killing in response to certain chemotherapeutic drugs, which led to the prediction that DNA MMR-deficient tumors might be resistant to standard adjuvant chemotherapy; this was later proven to be the case in clinical trials. He continues to work on colorectal cancer, including studies of the epigenetic changes (changes in DNA methylation and microRNAs) in cancer tissues and blood. Insights gained into the genesis of CRC from his lab have led to the development of preventive strategies, some of which utilize compounds present in foods that are commonly eaten in populations with low CRC incidences. More recent studies are focused on developing simple, effective, and patient-friendly means to screen for early CRC, and the host’s immune response to cancer.
Rick is an active clinician and teacher. He has been funded continuously by the NIH since 1979, has served on multiple NIH (and other) Study Sections and will be Chair of the Clinical Integrative Molecular Gastroenterology Study Section in 2014. He has published ~340 papers, written authoritative chapters for several textbooks of Internal Medicine, Gastroenterology and Genetics, has been elected into the Association of American Physicians, and has trained numerous post-doctoral fellows and graduate students who have followed him into the study of colorectal cancer. He was honored with the GI Oncology Section Mentoring Award in 2011. He was the American Gastroenterological Association President from 2011-12. In February, 2014, he began a sabbatical to write a book for popular consumption on Lynch Syndrome from a personal perspective, including the pursuit of the cause of this disease in his own family.
MD, PhD, University of Texas MD Anderson Cancer Clinic
Dr. Russell R. Broaddus is Director of the Cancer Biomarker Pathology Fellowship Program, Co-director of the M.D./Ph.D. Program of MD Anderson and The University of Texas Medical School at Houston, Associate Professor in the Department of Pathology, and member of the graduate faculty of The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS).
Over the course of his career, Dr. Broaddus has been well recognized for his educational and scientific achievements. In particular, he is the 2010-2013 recipient of the MD Anderson Faculty Scholar Award. Furthermore he received the John P. McGovern Outstanding Teacher Award at the GSBS for 2005-2006.
Dr. Broaddus received his M.D. degree from The University of Texas Medical School at Houston and Ph.D. degree from the GSBS in 1994. Afterward, he completed his postgraduate training in Anatomic Pathology at the Baylor College of Medicine Affiliated Hospitals in 1998.
After his postgraduate training, Dr. Broaddus was named Assistant Professor in the Department of Pathology at the Baylor College of Medicine in 1998. In 1999, he joined the MD Anderson faculty as an Assistant Professor in the Department of Pathology. He went on to be named to the GSBS faculty in 2001 and promoted to his current position of Associate Professor at MD Anderson in 2005.
Dr. Broaddus was appointed Co-director of the M.D./Ph.D. Program and named Director of the program’s Cancer Track in 2000. Also, he was named Director of the Cancer Biomarker Pathology Fellowship Program in 2006. Dr. Broaddus has also been Co-director of the MD Anderson Multidisciplinary Gynecological Tumor Bank since 2001, a member of the M.D./Ph.D. Program Committee since 1999, and a member of the MD Anderson Human Biology and Patient-Based Research Ph.D. Training Program since 2005.
Dr. Broaddus has been a principal investigator or co-investigator for nearly 20 grant-funded research projects, including the National Cancer Institute-sponsored SPORE in Uterine Cancer. Also, he has been a grant reviewer for several funding agencies. Over the course of his career, Dr. Broaddus has authored more than 100 articles published in peer-reviewed journals, 8 invited articles, 3 book chapters, and numerous abstracts.
MS, LGC - Ohio State University Comprehensive Cancer Center
Heather Hampel, MS, CGC, is a cancer genetic counselor at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). Hampel received her bachelor’s degree in molecular genetics from Ohio State in 1993 and her master’s degree in human genetics from Sarah Lawrence College in 1995. After graduation, she worked as a cancer genetic counselor at Memorial Sloan-Kettering Cancer Center in New York City before coming to the OSUCCC – James in 1997. She was appointed in 2001 as a clinical instructor in the Department of Internal Medicine, Division of Human Genetics, where she is now a full professor. Hampel’s clinical duties include providing comprehensive cancer genetic consultations to individuals and families with a history of cancer, a task that includes extensive documentation of cancers in the family, risk assessment, screening recommendations and genetic testing. Hampel’s research interests include screening all colorectal and endometrial (uterine) cancer patients for Lynch syndrome, an inherited condition that predisposes families to multiple cancers. She recently completed a five-year term on the American Board of Genetic Counselors, for which she was president in 2009-10. Hampel also is a part of the Facing Our Risk for Cancer Empowered (FORCE) medical advisory board and an expert for Bright Pink, a national non-profit organization devoted to prevention and early detection of breast and ovarian cancers in young women while providing support for high-risk individuals.
MS, LGC - University of Utah Huntsman Cancer Institute
Kory Jasperson, MS, CGC is a board-certified genetic counselor at Huntsman Cancer Institute with 10 years of clinical cancer genetics experience. He is a panel member of four NCCN guidelines involving genetics and vice-chair of both the Colorectal Cancer Screening and the Genetic/Familial High-Risk Assessment: Colorectal Guidelines. He is also a co-founder of the Lynch Syndrome Screening Network (LSSN) and a board member for the Hereditary Colon Cancer Foundation. His primary research interest includes hereditary GI syndromes.
MD, MPH - New York - Presbyterian/Columbia University
Dr. Kastrinos is a clinical gastroenterologist with academic interests related to the genetics, screening and primary prevention of gastrointestinal tumors, primarily colorectal and pancreatic cancer. She obtained specialty training in gastroenterology at Brigham and Women’s Hospital with a focus on clinical cancer genetics obtained through her clinical research endeavors at Dana Farber Cancer Institute, Boston MA. Dr. Kastrinos has clinical expertise in the evaluation of patients at risk for hereditary gastrointestinal cancer syndromes. Her research focus is in optimizing the identification of patients with inherited cancer syndromes and promoting cancer screening and prevention. Dr. Kastrinos joined the faculty of the Division of Digestive and Liver Diseases at Columbia University Medical Center in New York City in 2008 and is an active member of the Herbert Irving Comprehensive Cancer Center. She established and directs a multi-disciplinary specialty clinic at the Cancer Center for risk assessment and genetic evaluation of familial gastrointestinal malignancies, notably colorectal and pancreatic cancer. She has received numerous research awards and funding from the American Cancer Society, the National Cancer Institute, and the American Society of Gastrointestinal Endoscopy. She has numerous peer-reviewed publications related to the epidemiology of inherited colorectal cancer syndromes and the development of risk assessment tools to identify individuals at risk for hereditary cancer syndromes. Dr. Kastrinos also serves as a collaborator on a funded study to expand clinical prediction models for colorectal cancer and polyposis syndromes, a natural extension of the research she has completed to date. She is a co-investigator and the site principal investigator at Columbia University Medical Center for a collaborative research effort funded by the Great Lakes-New England Consortium of the Early Detection Research Network (EDRN). This program investigates colorectal cancer biomarker discovery through the Cancer of the Pancreas Screening (CAPS) multicenter collaborative effort addressing pancreatic cancer among subjects with a genetic predisposition.
MD - University of Texas MD Anderson Cancer Clinic
Dr. Lu is Professor in the Department of Gynecologic Oncology and Reproductive Medicine and holds the J. Taylor Wharton Distinguished Chair in Gynecologic Oncology. Her main clinical interests include the surgical and medical treatment of women with ovarian and endometrial cancers, as well as the management of women at genetically high risk for these cancers. She serves as Co-Director for the MD Anderson Clinical Cancer Genetics Program and Director of the High Risk Ovarian Cancer Screening Clinic. She is a national leader in the cancer genetics field and has published seminal articles on hereditary gynecologic cancers. In addition, she serves as Director of the Uterine Cancer Research Program (UCRP) and Principal Investigator of the NCI-sponsored Uterine Cancer Specialized Program of Research Excellence (SPORE). She leads a research team that aims to apply laboratory-based findings to improving the care of gynecologic cancer patients. She receives support for her research from the National Cancer Institute, the Lynne Cohen Foundation, the American Gynecologic and Obstetric Society, and the Ovarian Cancer Research Fund. She has published numerous articles and book chapters and has served as a visiting professor at many academic institutions. She has served on the American Society of Clinical Oncology (ASCO) Cancer Prevention Committee, the NCI PDQ Editorial Board for Cancer Genetics and the American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice Bulletins. In addition, she takes pride in having mentored many clinical fellows and trainees and has been awarded an M.D. Anderson Outstanding Educator Award. She has consistently been featured as one of America’s Top Doctors.
Daniel Luba was accepted into medical school immediately after high school graduation and completed a combined six-year undergraduate and medical school program at Boston University Medical School, where he received the Henry J. Bakst Award in Community Medicine. He did his Internship and Residency in Internal Medicine at Boston VA Medical Center in Boston, MA. Dr. Luba then moved to California and completed a Fellowship in Gastroenterology at Stanford University Medical Center. He is Board Certified in Gastroenterology. Dr. Luba is the managing partner of Gastroenterology Consultants Medical Group, Inc., Medical Director of the Monterey Bay Endoscopy Center, LLC, and President of the Monterey Bay GI Research Institute, Inc. For the years 2007 to 2013 Dr. Luba was selected by Best Doctors as one of the Best Doctors in America, an organization that selects its members through a peer-appointed process. Dr. Luba does all endoscopic procedures and has a special interest in Lynch and Familial Polyposis Syndromes.
PhD, MPH - University of Texas MD Anderson Cancer Clinic
Susan K. Peterson, PhD, MPH, is Professor of Behavioral Science at MD Anderson Cancer Center. A major focus of Dr. Peterson's research is psychosocial and behavioral outcomes of genetic testing for hereditary cancer syndromes in cancer survivors and their families, as well as the integration of genetic services into general oncology care. She has led and collaborated on studies of cancer survivors' and families' decision-making about genetic testing, and the subsequent psychological and behavioral impact of those decisions. Her research has also evaluated colorectal cancer screening in high risk populations, including Lynch syndrome and familial colorectal cancer. An ongoing theme of Dr. Peterson's research has been the development and testing of novel, e-Health and mobile health applications for behavioral intervention and assessment. These studies include an Internet-based psychosocial intervention for adolescents and young adults with familial adenomatous polyposis, and a social media-based intervention to facilitate communication about genetic risk in Lynch syndrome families. Dr. Peterson’s research is supported by the National Institutes of Health, the American Cancer Society, and the Duncan Family Institute for Cancer Prevention and Risk Assessment at MD Anderson. She serves on the National Cancer Institute’s PDQ Editorial Board for Cancer Genetics and is active on committees for the Hereditary Colon Cancer Foundation. Dr. Peterson received her PhD in Behavioral Sciences from the University of Texas School of Public Health and her Masters of Public Health degree from the University of Michigan.